Published: 5 August 2019
Author(s): Bouwe P. Krijthe, Maud A.W. Hermans, Carolina A.M. Schurink, Paul L.A. van Daele
Issue: August 2019
Section: Letter to the Editor

Recently, one of our patients was admitted to the Intensive Care Unit with a severe listeria sepsis while using adalimumab, an anti- TNFα biological. It is a 50-year old man of Moroccan descent with Behçet's disease who was being treated with adalimumab for a year when he presented with fever and hypotension without any other focal symptoms. When blood cultures revealed Listeria monocytogenes, he was treated with amoxicillin and recovered uneventfully. No cause for the Listeria infection could be identified.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.